Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human coronavirus humoral responses

Sensitive and specific SARS-CoV-2 antibody assays remain critical for community and hospital-based SARS-CoV-2 sero-surveillance. With the rollout of SARS-CoV-2 vaccines, such assays must be able to distinguish vaccine from natural immunity to SARS-CoV-2 and related human coronaviruses. Here, we developed and implemented multiplex microsphere-based immunoassay strategies for COVD-19 antibody studies that incorporates spike protein trimers of SARS-CoV-2 and the endemic seasonal human coronaviruses (HCoV), enabling high throughout measurement of pre-existing cross-reactive antibodies. We varied SARS-CoV-2 antigen compositions within the multiplex assay, allowing direct comparisons of the effects of spike protein, receptor-binding domain protein (RBD) and nucleocapsid protein (NP) based SARS-CoV-2 antibody detection. Multiplex immunoassay performance characteristics are antigen-dependent, and sensitivities and specificities range 92–99% and 94–100%, respectively, for human subject samples collected as early as 7–10 days from symptom onset. SARS-CoV-2 spike and RBD had a strong correlative relationship for the detection of IgG. Correlation between detectable IgG reactive with spike and NP also had strong relationship, however, several PCR-positive and spike IgG-positive serum samples were NP IgG-negative. This spike and NP multiplex immunoassay has the potential to be useful for differentiation between vaccination and natural infection induced antibody responses. We also assessed the induction of de novo SARS-CoV-2 IgG cross reactions with SARS-CoV and MERS-CoV spike proteins. Furthermore, multiplex immunoassays that incorporate spike proteins of SARS-CoV-2 and HCoVs will permit investigations into the influence of HCoV antibodies on COVID-19 clinical outcomes and SARS-CoV-2 antibody durability.


INTRODUCTION
existing antibody cross-reactivity with SARS-CoV S glycoprotein (36, 37), we validated 120 improvements to assay specificity by the concurrent measurement of SARS-CoV-2 and HCoV-121 specific immunoglobulin G (IgG) in a multiplex approach and report the stimulation of cross-122 reactive antibody responses across ARIC, EPICC and JMS cohorts. Furthermore, we 123 standardized SARS-CoV-2 and HCoV MMIA SARS-CoV-2 IgG detection in paired venous and 124 capillary blood specimens collected by serum separator tubes (SST) and dried blood spots 125 (DBS), respectively.

126
The objectives of this study were to develop and validate a high throughput antigen 127 based assay which can discriminate SARS-CoV-2 from seasonal human coronavirus (HCoV) 128 infections, as well as SARS-CoV-2 vaccination, including from specimens collected through self-

192
For each 96-well plate, a multiplex master mix of antigen-coupled microspheres was made by diluting 100 µL of each antigen-coupled microsphere working stock into 10 mL (1:100) 1XPBS 194 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

205
Samples were incubated at room temperature for 45 minutes with agitation (900 rpm), 206 and plates were washed three times by an automated plate washer. Secondary antibody (goat 207 anti-human IgG cross-absorbed biotin-conjugated or goat anti-human IgM cross-absorbed 208 biotin-conjugated; Thermo Fisher Scientific, Waltham, MA) was diluted 1:5000 in 1XPBS + 209 0.05% Tween20 (PBST) and 100 µL of each secondary was added to each well and incubated 210 for 45 minutes with agitation, and plates were washed three times. Streptavidin-phycoerythrin 211 (Bio-Rad) was diluted 1:1000 in PBST and 100 µL was then added to each well and incubated 212 for 30 minutes with agitation, and plates were washed three times. Lastly, 100 µL of PBST was 213 added to each well and plates were resuspended by agitation for 5 minutes. Plates were read 214 on Bio-Plex 200 multiplexing systems (Bio-Rad) with PMT voltage setting to the High RP1 target To establish threshold cutoffs for SARS-CoV-2 spike protein-specific antibody reactivity, 221 we tested 127 archival acute and convalescent human serum samples from ARIC. Acute and 222 convalescent serum samples were collected within approximately three and twenty-eight days 223 of symptom onset, respectively. We established a cut-off of three standard deviations above the

243
Sidak's multiple comparison were also utilized. When normality was not met, non-parametric 244 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.   This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted February 12, 2021. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.21251518 doi: medRxiv preprint probability distributions three standard deviations above the mean (99.7%) of these ARIC CoV-2 RT-PCR confirmed subjects enrolled in the ongoing EPICC protocol were applied for  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted February 12, 2021.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

462
CoV and MERS-CoV spike proteins. Threshold cutoffs for SARS-CoV and MERS-CoV spike 463 reactive IgG were similarly set with ARIC sera as detailed for SARS-CoV-2 spike (Fig. 4A). An This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted February 12, 2021. ;https://doi.org/10.1101https://doi.org/10. /2021 primates (NHP) model to inform the stimulation of HCoV cross-reactive antibodies. NHP had no 504 evidence of de novo IgG reactivity with HCoV-HKU1 and HCoV-OC43 spike proteins after 505 SARS-CoV-2 challenge and seroconversion (Fig. 5A). We extrapolated the 99.7% indeterminate 506 range of SARS-CoV, SARS-CoV-2 and MERS-CoV spike protein reactive IgG as a cutoff for 507 HCoV reactive antibodies (Fig. 4A). We found that IgG reactivity with HCoV spike proteins in the 508 SARS-CoV-2 PCR positive patient serum samples were significantly higher than those in 509 SARS-CoV-2 naïve ARIC cohort. We found significant geometric mean IgG increases of HCoV-510 OC43,26,518 (25,131 CI) and 29,454 (28,167 CI)  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted February 12, 2021.   This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10. 1101/2021 In this study, we have demonstrated that use of a multiplex microsphere-based 556 immunoassay (MMIA) built using Luminex xMAP-based technology in which individual 557 microspheres are bound to pre-fusion stabilized S glycoprotein trimers of SARS-CoV-2 and the 558 seasonal endemic HCoVs enables sensitive and specific detection of SARS-CoV-2 IgG 559 antibodies. Our SARS-CoV-2 spike-based MMIA strategies have sensitivities ranging 94 -99 % 560 as early as 7 -10 days after symptom onset in PCR-confirmed cases of SARS-CoV-2 infection 561 and 100% specificity for SARS-CoV-2 IgG, comparable with several other EUA serology tests 562 (6). Conserved epitopes present in the prefusion stabilized native-like trimeric S glycoprotein 563 oligomers (spike protein) are the likely major factor in the observed cross reactions between the 564 coronavirus S glycoproteins, affecting specificity for some serology assays. By using HCoV-565 HKU1 and HCoV-OC43 spike proteins to capture pre-existing antibodies that would be cross-566 reactive with SARS-CoV-2 spike, the assay had a 100% specificity for SARS-CoV-2 serology.

567
Importantly, the ability to simultaneously capture SARS-CoV-2 spike and NP-specific antibodies 568 within a single assay will facilitate high-throughput approaches for differentiating antibody 569 responses between SARS-CoV-2 natural infections and vaccinations.

570
The magnitude of the antibody response to SARS-CoV-2 infection has been associated 571 with COVID-19 severity (51).This was apparent in our validation tests as geometric mean IgG 572 levels were consistently elevated in sera from the JMS cohort, comprised of all hospitalized 573 patients, whereas sera from the EPICC cohort had lower geometric mean IgG to SARS-CoV-2 574 antigens, of which the majority of EPICC study participants were outpatients. Interestingly, 575 geometric mean IgG level,20,542 MFI (18,440 CI) to SARS-CoV-2 spike determined by 576 testing with the β-CoV MMIA was lower than the geometric mean IgG levels spike, 25,226 MFI 577 (23,490 CI) in the SARS-2 spike/NP MMIA. One possibility is that in the β-CoV MMIA, 578 inclusion of spike and RBD which represent overlapping epitopes leads to competition for 579 antibodies, decreasing overall MFI levels to either S glycoprotein antigen individually. The effect 580 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted February 12, 2021. ;https://doi.org/10.1101https://doi.org/10. /2021 when concentrations of circulating SARS-CoV-2 sera IgG begins to wane. Whereas establishing 582 the SARS-CoV-2 spike protein and NP MMIA will have utility for the future differentiation 583 between antibody responses to SARS-CoV-2 vaccination and natural infection induced antibody 584 responses, with some inherent limitations to sensitivity and specificity.

585
Of additional importance, the MMIA approach demonstrated de novo IgG cross-reactivity prior humoral memory to seasonal HCoV appears necessary to drive cross-reactivity. Overall, the OC43 S glycoprotein only shares 30 to 40% amino acid sequence identity/similarity with 608 SARS-CoV-2 S glycoprotein (37). The S1 subunit, wherein resides the RBD, has more 609 sequence variance among OC43 and SARS-CoV-2, in contrast to the S2 subunit heptad repeat 610 regions where amino acid sequence similarity is between 50 to 75%. It would seem unlikely that 611 a SARS-CoV-2 de novo IgG response would result in cross-reactive antibodies that would bind 612 at immunoassay saturation to distantly-related seasonal β-CoVs. However, we did observe  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.   This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint this version posted February 12, 2021. ; https://doi.org/10.1101/2021.02.10.21251518 doi: medRxiv preprint   This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.